Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | El‐Feky, Yasmin A. | |
| dc.contributor.author | Mostafa, Dalia A. | |
| dc.contributor.author | Al-Sawahli, Majid M. | |
| dc.contributor.author | El‐Telbany, Rania Farag A. | |
| dc.contributor.author | Zakaria, Sherin | |
| dc.contributor.author | Fayez, Ahmed M. | |
| dc.contributor.author | Ahmed, Kawkab A. | |
| dc.contributor.author | Ebtesam M Alolayan | |
| dc.contributor.author | Dalia Farag A El-Telbany | |
| dc.date.accessioned | 2020-03-18T10:11:22Z | |
| dc.date.available | 2020-03-18T10:11:22Z | |
| dc.date.issued | 2020-03 | |
| dc.description.abstract | Objective To enhance bioavailability of timolol (TML) and utilize alternatives for traditional eye drops for more patient compliance, this study was aiming to develop biodegradable orally dissolving strips (ODSs) of TML for treatment of primary open-angle glaucoma (POAG). Methods Novel ODSs of TML were formulated and optimized using solvent casting method according to full factorial design (31 .22 ). TML ODSs were charac- terized with respect to many parameters. In-vivo test was carried out using four groups of 24 New Zealand albino rabbits. POAG was induced by subconjunctival treatment of betamethasone. Histopathological examination and oxidative stress markers assay were carried out. Key findings The optimized formula (F9) exhibited a remarkably 15-s disinte- gration time and 96% dissolution rate after 10 min. The results revealed a potent significant inhibitory effect of the optimized TML ODS to reduce IOP in induced rabbits in comparison with control rabbits and TML eye drops-treated rabbits. The formula showed also high activity against oxidative stress and absence of histopathological changes in iridocorneal angle and cornea. Conclusion The ODSs could be a promising alternative delivery system for eye drops with more compliance to enhance delivery and therapeutic activity of TML in treatment of POAG. | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=23102&tip=sid&clean=0 | |
| dc.identifier.citation | Tsai C-H et al. Ocular drug delivery: role of degradable polymeric nanocar- riers for ophthalmic application. Int J Mol Sci 2018; 19: 2830. 2. Weinreb RN et al. The pathophysiol- ogy and treatment of glaucoma: a review. JAMA 2014; 311: 1901–1911. 3. Khawaja AP et al. Genome-wide anal- yses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. Nat Genet 2018; 50: 778– 782. 4. Boland MV et al. Comparative effec- tiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158: 271–279. 5. Kass MA et al. The Ocular Hyperten- sion Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or pre- vents the onset of primary open-angle glaucoma. Arch Ophthalmol 1960; 2002: 701–713; discussion 829-30. 6. Cherecheanu AP et al. Ocular perfu- sion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol 2013; 13: 36–42. 7. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin Ophthal- mol 2005; 16: 79–83. 8. Moore D et al. Dysfunctional regula- tion of ocular blood flow: a risk factor for glaucoma? Clin Ophthalmol 2008; 2: 849. 9. Cioffi GA. Ischemic model of optic nerve injury. Trans Am Ophthalmol Soc 2005; 103: 592. 10. Cioffi GA et al. Chronic ischemia induces regional axonal damage in experimental primateoptic neuropa- thy. Arch Ophthalmol 2004; 122: 1517–1525. 11. Adams CM et al. Glaucoma-next gen- eration therapeutics: impossible to possible. Pharm Res 2019; 36: 25. 12. Li X et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008; 363: 177–182. 13. Manjunatha KM, Kulkarni GT. Design, development and evaluation of controlled release levobunolol hydrochloride ocular inserts for glau- coma therapy. J Chronother Drug Deliv 2012; 3: 87–97. 14. Mitra AK. Overview of Ocular Drug Delivery. Ophthalmic Drug Delivery Systems, 2nd edn. CRC Press, 2003: 20–31. 15. Heel RC et al. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979; 17: 38–55. 16. Lavik E et al. Novel drug delivery sys- tems for glaucoma. Eye 2011; 25: 578. 17. Morsi NM et al. Improved bioavail- ability of timolol maleate via transder- mal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. J Adv Res 2016; 7: 691–701. 18. Rodr- ıguez I et al. Enhancement and inhibition effects on the corneal per- meability of timolol maleate: Poly- mers, cyclodextrins and chelating agents. Int J Pharm 2017; 529: 168– 177. 19. Lai KL et al. Orally-dissolving film for sublingual and buccal delivery of ropi- nirole. Colloids Surf B 2018; 163: 9– 18. 20. Senel S et al. Recent developments in buccal and sublingual delivery sys- tems. Exp Opin Drug Deliv 2012; 9: 615–628. 21. Mohapatra S et al. Nanocarriers for Drug Delivery: Nanoscience and Nan- otechnology in Drug Delivery. Elsevier, 2018. 22. Zheng Y et al. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the Singa- pore Malay eye study. Invest Ophthal- mol Vis Sci 2010; 51: 3399–3404. 23. Garsuch V, Breitkreutz J. Comparative investigations on different polymers for the preparation of fast-dissolving oral films. J Pharm Pharmacol 2010; 62: 539–545. 24. Nair AB et al. In vitro techniques to evaluate buccal films. J Controlled Release 2013; 166: 10–21. 25. Bhyan B et al. Orally fast dissolving films: innovations in formulation and technology. Int J Pharm Sci Rev Res 2011; 9: 9–15. 26. Ghodake PP et al. Mouth dissolving films: innovative vehicle for oral drug delivery. Polymer. 2013; 9: 20. 27. Smriti T. Mouth dissolving films: a review. Int J Pharma Bio Sci 2013; 4: 899–908. 28. Peh KK, Wong CF. Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive proper- ties. J Pharm Pharm Sci 1999; 2: 53– 61. 29. Tedesco MP et al. Gelatin/hydrox- ypropyl methylcellulose matrices— polymer interactions approach for oral disintegrating films. Mater Sci Eng C 2016; 69: 668–674. 30. Nagar P et al. Insights into polymers: film formers in mouth dissolving films. Drug Invent Today 2011; 3: 280–289. 31. Bala R et al. Design optimization and in vitro-in vivo evaluation of orally dissolving strips of clobazam. J Drug Deliv 2014; 2014: 1–15. 32. ElGohary AA, Elshazly LHM. Pho- topic negative response in diagnosis of glaucoma: an experimental study in glaucomatous rabbit model. Int J Ophthalmol 2015; 8: 459. 33. Pereira FQ et al. Comparison of a rebound and an applanation tonome- ter for measuring intraocular pressure in normal rabbits. Vet Ophthalmol 2011; 14: 321–326. 34. Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. Elsevier Health Sciences, 2008. 35. Biswal B et al. Formulation and evalu- ation of repaglinide buccal tablet: ex vivo bioadhesion study and ex vivo permeability study. J Appl Pharm Sci 2014; 4: 96. 36. Irfan M et al. Orally disintegrating films: a modern expansion in drug delivery system. Saudi Pharm J 2016; 24: 537–546. 37. Siddiqui MN et al. A short review on “A novel approach in oral fast dissolv- ing drug delivery system and their patents”. Adv Biol Res 2011; 5: 291– 303. 38. Cao N et al. Effects of various plasti- cizers on mechanical and water vapor barrier properties of gelatin films. Food Hydrocolloids 2009; 23: 729–735. 16 | en_US |
| dc.identifier.doi | https://doi.org/10.1111/jphp.13239 | |
| dc.identifier.other | https://doi.org/10.1111/jphp.13239 | |
| dc.identifier.uri | https://t.ly/nr5Bn | |
| dc.language.iso | en_US | en_US |
| dc.publisher | royal pharmaceutical society | en_US |
| dc.relation.ispartofseries | Journal of Pharmacy and Pharmacology,; | |
| dc.subject | university of timolol | en_US |
| dc.subject | primary open-angle glaucoma | en_US |
| dc.subject | orally dissolving strips | en_US |
| dc.subject | fast release | en_US |
| dc.subject | intraocular pressure | en_US |
| dc.title | Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits | en_US |
| dc.type | Article | en_US |